Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Adrenocortical Carcinoma 1

Interventions

cixutumumab 2cabozantinib 2Trastuzumab 2Specimen Handling 2Radiotherapy 2Mitotane 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Cisplatin 2tipifarnib 1sodium thiosulfate 1gossypol acetic acid 1entinostat 1cemiplimab 1Vincristine 1Tamoxifen 1Ritonavir 1Oxaliplatin 1Nivolumab 1Microscopy, Electron 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Floxuridine 1Etoposide 1Dichlorodiphenyldichloroethane 1Dexamethasone 1Cytoreduction Surgical Procedures 1CYT-6091 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adrenocortical Carcinoma × Dichlorodiphenyldichloroethane × Clear all
NCT00778817 2014-04-29

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
20 enrolled 17 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡